Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2023
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Restless legs syndrome
- Focus Pharmacokinetics; Registrational
- Sponsors GlaxoSmithKline
- 07 Jun 2016 Results of pooled analysis of three trials (NCT00298623, NCT00365352 and NCT01332305)published in the Clinical Therapeutics
- 19 Apr 2016 Results of pooled post hoc analysis of 3 Phase III trials (NCT00298623, NCT00365352, NCT01332305) published in the CNS Drugs
- 11 Apr 2016 Results of three phase III studies published in the CNS Drugs.